EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Curriculum Vitae

Personal information

Anne-Marie Abrahamsson Ciupitu

Work experience

Apr 2025 – ongoing: Pharmaceutical inspector, Medicinal Products Agency, Uppsala, Sweden
Dec 2022 – Feb 2025: Associate Director/Qualified Person, Sweden BioManufacturing Center, AstraZeneca AB, Södertälje, Sweden
Aug 2019 – Nov 2022: Quality Specialist (internal auditor), Sweden Operations, AstraZeneca AB, Södertälje, Sweden
Oct 2016 – Aug 2019: Quality Director, Apotek Produktion & Laboratorier AB (APL), Stockholm, Sweden
April 2012 – Sep 2016: Quality Compliance Manager, Valneva Sweden AB (previously Crucell Sweden AB), Solna, Sweden
Oct 2007 – Feb 2012: Director QA/QC, Orexo AB, Uppsala, Sweden
Jan 2007 – Sep 2007: QA Manager, Wyeth Biotech, Stockholm, Sweden
Jul 2002 – Dec 2006: Sr QA Specialist, Wyeth BioPharma, Stockholm, Sweden
Jan 2001 – Jun 2002: QA Specialist, Genetics Institute, Stockhom, Sweden
May 2000 – Dec 2000: Researcher, Karolinska Institute, Solna, Sweden

Education and training

Environmental toxicology, Stockholm University, Sweden, 5 weeks 2009
Industrial galenical pharmacy, University of Uppsala, Sweden, 5 weeks 2008
Pharmacology, University of Uppsala, Sweden, 10 weeks 2005
Ph.D., Immunobiology, Karolinska Institute, Sweden, 1993 - 2000
M.Sc., Biology (major in microbiology), Stockholm University, Sweden, 1989 - 1994

Additional information

Publications

Projects

Kono K, Petersson M, Ciupitu AM, Wen T, Klein G, Kiessling R (1995). Methylcholanthrene-induced mouse sarcomas express individually distinct major histocompatibility complex class I-associated peptides recognized by specific CD8+ T-cell lines. Cancer Res. 55(23):5648-5655.
https://pubmed.ncbi.nlm.nih.gov/7585649

Ciupitu AM, Petersson M, ODonnell CL, Williams K, Jindal S, Kiessling R, Welsh RM (1998). Immunization with a lymphocytic choriomeningitis virus peptide mixed with heat shock protein 70 results in protective antiviral immunity and specific cytotoxic T lymphocytes. J Exp Med. 187(5):685-691.
https://pubmed.ncbi.nlm.nih.gov/9480978

Thesis at Karolinska Institute, 2000: Hsp70 in immunotherapy : a potential vector in cancer and viral vaccines

Memberships

Other Relevant Information